Arcadia Biosciences (RKDA) Consolidated Net Income (2014 - 2026)

Arcadia Biosciences (RKDA) has reported Consolidated Net Income for 13 consecutive years, with -$496000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Consolidated Net Income rose 1.0% year-over-year to -$496000.0; the trailing twelve-month figure through Jun 2026 stood at -$3.5 million (up 15.35% YoY), and the FY2025 full-year result was -$1.8 million, up 66.87% from the prior year.
• Consolidated Net Income rose to -$496000.0 in Q2 2026 per RKDA's latest filing, from -$1.4 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $1.1 million in Q2 2023 and bottomed at -$4.6 million in Q1 2022.
• Historically, Consolidated Net Income has averaged -$1.7 million across 5 years, with a median of -$1.4 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Consolidated Net Income surged 130.23% in 2023, then slumped 278.3% in 2024.
• Over 5 years, Consolidated Net Income stood at -$4.3 million in 2022, then jumped by 84.24% to -$682000.0 in 2023, then plunged by 278.3% to -$2.6 million in 2024, then surged by 46.71% to -$1.4 million in 2025, then surged by 63.93% to -$496000.0 in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$496000.0, -$1.4 million, and -$1.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.